MD1 Archives - Page 5 of 6 - 2021 CMSC Annual Meeting

October 25, 2021

Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data

Background: The majority of real-world data (RWD) on disease-modifying treatments (DMTs) for multiple sclerosis (MS) is based on clinical...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS

Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab

Background: A global pandemic of COVID-19 has resulted in over 78 million cases as of 23 December 2020. Risks of COVID-19 in people with...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Characterization of Treatment-Naïve Patients with Multiple Sclerosis Newly Initiating Disease-Modifying Therapy

Background: The treatment landscape for multiple sclerosis (MS) continues to evolve and many disease-modifying therapies (DMTs) with...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with Suboptimal Response to Prior Disease-Modifying Therapies: Data from the CASTING Study

Background: Patients with relapsing-remitting multiple sclerosis (RRMS) often experience disease activity despite receiving a...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Immunoglobulin Kinetics and Infection Risk after Long-Term Inebilizumab Treatment for Neuromyelitis Optica Spectrum Disorder

Background: Long-term use of B-cell depleting monoclonal antibodies is associated with reduced immunoglobulin (Ig) levels that can...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Real-Life Experience with Ocrelizumab in Older Patients at an Academic MS Center

Background: Ocrelizumab (OCR) is a B-Cell depleting humanized monoclonal antibody FDA-approved for treatment of relapsing remitting...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity

Background: NEDA or No evidence of disease activity (relapses, MRI lesions and disease progression) is increasingly used as a meaningful...

Read More →

Poster-Case Reports / Case Series

October 25, 2021

Multiple Sclerosis-like Features in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Red Flag, Red Herring, or Regular Occurrence?

Background: MOG antibody-associated disease (MOGAD) is an inflammatory demyelinating disorder characterized by IgG antibodies against...

Read More →

Poster-Case Reports / Case Series

October 25, 2021

Multiple Sclerosis in a Patient with Neurofibromatosis Type-1

Background: The association of multiple sclerosis (MS) and neurofibromatosis type 1 (NF1) has been rarely reported. Objectives: To report a...

Read More →

2021 CMSC Annual Meeting

Tag: MD1

Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data

Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS

Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab

Characterization of Treatment-Naïve Patients with Multiple Sclerosis Newly Initiating Disease-Modifying Therapy

Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with Suboptimal Response to Prior Disease-Modifying Therapies: Data from the CASTING Study

Immunoglobulin Kinetics and Infection Risk after Long-Term Inebilizumab Treatment for Neuromyelitis Optica Spectrum Disorder

Real-Life Experience with Ocrelizumab in Older Patients at an Academic MS Center

MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity

Multiple Sclerosis-like Features in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Red Flag, Red Herring, or Regular Occurrence?

Multiple Sclerosis in a Patient with Neurofibromatosis Type-1

MAILING ADDRESS

CONTACT US

FOLLOW US